down arrow

Dyne Therapeutics, Inc.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US26818M1080
USD
19.85
1.3 (7.01%)

Dec 19

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

18.7320.11

52 Week

6.3626.22
Valuation
Technical
Day's Volume

CASH

4.12 M

Shareholding (Mar 2025)

FII

16.99%

Held by 109 FIIs

DII

22.13%

Held by 49 DIIs

Promoter

26.38%

How big is Dyne Therapeutics, Inc.?

22-Jun-2025

As of Jun 18, Dyne Therapeutics, Inc. has a market capitalization of $1.24 billion, with net sales of $0.00 million and a net profit of -$367.12 million over the latest four quarters. The company reported shareholder's funds of $629.84 million and total assets of $691.23 million as of Dec 24.

Market Cap: As of Jun 18, Dyne Therapeutics, Inc. has a market capitalization of 1,235.77 million, categorizing it as a Small Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, Dyne Therapeutics, Inc. reported net sales of 0.00 million and a net profit of -367.12 million.<BR><BR>Balance Sheet Snapshot: As of Dec 24, the company reported shareholder's funds of 629.84 million and total assets of 691.23 million.

Read More

What does Dyne Therapeutics, Inc. do?

22-Jun-2025

Dyne Therapeutics, Inc. is a biotechnology company focused on developing therapeutics for genetically driven diseases, with a market cap of approximately $1.24 billion and a recent net profit of -$115 million. The company is classified as small-cap and operates in the Pharmaceuticals & Biotechnology industry.

Overview: <BR>Dyne Therapeutics, Inc. is a biotechnology company focused on developing therapeutics for patients with genetically driven diseases, operating within the Pharmaceuticals & Biotechnology industry and classified as a small-cap company.<BR><BR>Financial Snapshot: <BR>Most recent Net Profit: -115 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 1,235.77 Million (Small Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -1.01 <BR>Return on Equity: -54.88% <BR>Price to Book: 1.85<BR><BR>Contact Details: <BR>Address: 830 Winter Street, WALTHAM MA: 02451 <BR>Tel: 1 781 7868230 <BR>Fax: 1 781 7868866 <BR>Website: https://www.dyne-tx.com/

Read More

Who are in the management team of Dyne Therapeutics, Inc.?

22-Jun-2025

As of March 2022, the management team of Dyne Therapeutics, Inc. includes Mr. Jason Rhodes as Executive Chairman and Mr. Joshua Brumm as President, CEO, and Director.

As of March 2022, the management team of Dyne Therapeutics, Inc. includes Mr. Jason Rhodes, who serves as the Executive Chairman of the Board, and Mr. Joshua Brumm, who is the President, Chief Executive Officer, and a Director.

Read More

Is Dyne Therapeutics, Inc. technically bullish or bearish?

20-Sep-2025

As of September 8, 2025, Dyne Therapeutics shows a mildly bearish trend with mixed technical indicators, underperforming the S&P 500 significantly with a year-to-date return of -40.92%.

As of 8 September 2025, the technical trend for Dyne Therapeutics, Inc. has changed from sideways to mildly bearish. The weekly MACD is mildly bullish, while the monthly MACD is bearish, indicating mixed signals. The RSI shows no signal on the weekly timeframe but is bullish on the monthly. Bollinger Bands are bullish weekly but mildly bearish monthly, and moving averages indicate a mildly bearish stance on the daily. The KST is bullish weekly but bearish monthly, and the OBV is mildly bearish weekly and mildly bullish monthly. <BR><BR>In terms of performance, Dyne Therapeutics has underperformed significantly against the S&P 500 over the longer term, with a year-to-date return of -40.92% compared to the S&P 500's 12.22%, and a one-year return of -59.46% versus 17.14%. This suggests a strong bearish sentiment overall, despite some short-term bullish indicators.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 1,894 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-1.02

stock-summary
Return on Equity

-72.25%

stock-summary
Price to Book

3.31

Revenue and Profits:
Net Sales:
(Quarterly Results - Jun 2025)
Net Profit:
-111 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
51.18%
0%
51.18%
6 Months
84.14%
0%
84.14%
1 Year
-18.31%
0%
-18.31%
2 Years
57.41%
0%
57.41%
3 Years
47.91%
0%
47.91%
4 Years
58.17%
0%
58.17%
5 Years
-6.19%
0%
-6.19%

Dyne Therapeutics, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News
Icon
No Recent News for the Company
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
0
EBIT Growth (5y)
-226.07%
EBIT to Interest (avg)
-251.07
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.01
Sales to Capital Employed (avg)
0
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
100.00%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
2.50
EV to EBIT
-2.52
EV to EBITDA
-2.53
EV to Capital Employed
-293.53
EV to Sales
NA
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
-54.88%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Bearish
Moving Averages
Bullish (Daily)
KST
Bullish
Bearish
Dow Theory
No Trend
No Trend
OBV
Mildly Bullish
Mildly Bearish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 61 Schemes (34.5%)

Foreign Institutions

Held by 109 Foreign Institutions (16.99%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is -70.35% vs -0.31% in Jun 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-115.30",
          "val2": "-71.60",
          "chgp": "-61.03%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.10",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-110.90",
          "val2": "-65.10",
          "chgp": "-70.35%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -34.55% vs -40.33% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-341.60",
          "val2": "-239.70",
          "chgp": "-42.51%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-317.40",
          "val2": "-235.90",
          "chgp": "-34.55%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoYstock-summary
Jun'25
Jun'24
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-115.30
-71.60
-61.03%
Interest
0.10
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-110.90
-65.10
-70.35%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is -70.35% vs -0.31% in Jun 2024

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-341.60
-239.70
-42.51%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-317.40
-235.90
-34.55%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -34.55% vs -40.33% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About Dyne Therapeutics, Inc. stock-summary
stock-summary
Dyne Therapeutics, Inc.
Pharmaceuticals & Biotechnology
Dyne Therapeutics Inc. is a biotechnology company focused on developing therapeutics for patients with genetically driven diseases. The Company’s FORCE platform therapeutics consists of an oligonucleotide payload that it designs to target the genetic basis of the disease. With its FORCE platform, the Company has the flexibility to deploy different types of oligonucleotide payloads with specific mechanisms of action that modify target functions. Using its FORCE platform, the Company is assembling a portfolio of muscle disease therapeutics, including its lead programs in myotonic dystrophy type 1 (DM1), Duchenne muscular dystrophy (DMD), and facioscapulohumeral dystrophy (FSHD). Its therapeutics consist of three components: a proprietary Fab, a clinically validated linker and an oligonucleotide payload that it attaches to its Fab using the linker. Its DM1 program is focused on the development of a potentially disease-modifying treatment for DM1.
Company Coordinates stock-summary
Company Details
830 Winter Street , WALTHAM MA : 02451
stock-summary
Tel: 1 781 7868230
stock-summary
https://www.dyne-tx.com/
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."